Gainers

• Cue Biopharma (NASDAQ:CUE) shares increased by 45.1% to $21.5 during Thursday's after-market session. The market value of their outstanding shares is at $42.3 million.
• Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 25.96% to $1.31. The company's market cap stands at $5.5 million.
• Akanda (NASDAQ:AKAN) shares rose 24.59% to $61.0. The company's market cap stands at $13.8 million.
• Emergent BioSolutions (NYSE:EBS) stock increased by 10.93% to $9.13. The market value of their outstanding shares is at $412.6 million. As per the news, the Q1 earnings report came out today.
• Cerus (NASDAQ:CERS) shares rose 10.34% to $2.24. The company's market cap stands at $384.7 million. As per the press release, Q1 earnings came out today.
• American Shared Hospital (AMEX:AMS) stock increased by 9.65% to $1.59. The market value of their outstanding shares is at $8.8 million.

Losers

• Summit Therapeutics (NASDAQ:SMMT) stock decreased by 24.1% to $16.3 during Thursday's after-market session. The company's market cap stands at $16.1 billion. As per the news, the Q1 earnings report came out today.
• Senseonics Holdings (NASDAQ:SENS) stock declined by 16.8% to $5.5. The market value of their outstanding shares is at $268.5 million.
• OSR Holdings (NASDAQ:OSRH) shares declined by 14.63% to $0.6. The market value of their outstanding shares is at $11.8 million.
• Calidi Biotherapeutics (AMEX:CLDI) stock declined by 10.51% to $0.21. The company's market cap stands at $1.9 million.
• Prelude Therapeutics (NASDAQ:PRLD) shares decreased by 9.32% to $4.74. The company's market cap stands at $345.9 million.
• Guardian Pharmacy Service (NYSE:GRDN) shares declined by 8.65% to $33.89. The company's market cap stands at $2.4 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.